Collaboration Agreement was Theravance Biopharma’s largest product and service line in fiscal 2025, bringing in $74.96M of $107.46M (70%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2020 | FY 2020 | FY 2020 | FY 2021 | FY 2021 | FY 2021 | FY 2021 | FY 2022 | FY 2022 | FY 2022 | FY 2022 | FY 2023 | FY 2023 | FY 2023 | FY 2023 | FY 2024 | FY 2024 | FY 2024 | FY 2025 | FY 2025 | FY 2025 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Future Potential Combination Products | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||
| Viatris Collaboration Agreement | — | — | — | $48.62M | — | — | — | $57.20M | — | — | — | — | — | — | — | ||||||||||||
| Collaboration Agreement | — | — | — | — | — | — | — | — | — | — | $64.38M | — | — | — | $74.96M | ||||||||||||
| Collaboration Revenue | — | — | — | $192.00K | — | — | — | $216.00K | — | — | — | — | — | — | — | ||||||||||||
| Collaborative Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||
| Milestone | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $25.00M | ||||||||||||
| Yupelri Monotherapy | $15.28M | $17.18M | $18.70M | — | $16.43M | $19.26M | $20.41M | — | $19.33M | $19.09M | — | $20.42M | $23.22M | $24.98M | — | ||||||||||||
| Product Sales | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||
| Licensing | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $7.50M | ||||||||||||
| Licensing Revenue | — | — | — | $2.50M | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||
| Viatris Royalties (Non-Us) | — | — | — | $30.00K | — | — | — | $7.00K | — | — | — | — | — | — | — | ||||||||||||
| Total | $15.28M | $17.18M | $18.70M | $51.35M | $16.43M | $19.26M | $20.41M | $57.42M | $19.33M | $19.09M | $64.38M | $20.42M | $23.22M | $24.98M | $107.46M |
Theravance Biopharma brought in $107.46M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Theravance Biopharma regrouped these lines after fiscal 2025, so the total does not compare directly with that year's $24.98M. Collaboration Agreement was the largest at $74.96M (69.8%), ahead of Milestone at $25.00M (23.3%) and Licensing at $7.50M (7.0%).
Theravance Biopharma began breaking out Collaboration Agreement in fiscal 2024, Milestone in fiscal 2025 and Licensing in fiscal 2025. Theravance Biopharma stopped reporting Viatris Collaboration Agreement ($57.20M in fiscal 2023), Yupelri Monotherapy ($24.98M in fiscal 2025), Licensing Revenue ($2.50M in fiscal 2022) and two others as separate lines.
United States was Theravance Biopharma’s largest region in fiscal 2025, bringing in $74.96M of $107.46M (70%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| United States | — | — | $64.38M | $74.96M | |||||
| Us | $51.12M | $57.20M | — | — | |||||
| Europe | $222.00K | $223.00K | — | $32.50M | |||||
| Asia | — | — | — | — | |||||
| Total | $51.35M | $57.42M | $64.38M | $107.46M |
Theravance Biopharma brought in $107.46M from its two regions in fiscal 2025, the year ended December 31, 2025. Theravance Biopharma regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $64.38M. United States was the largest at $74.96M (69.8%), ahead of Europe at $32.50M (30.2%).
Theravance Biopharma stopped reporting Us as a separate region after fiscal 2023, when it brought in $57.20M.
Collaborative Arrangement was Theravance Biopharma’s largest revenue line in fiscal 2023, bringing in $57.20M of $57.21M (100%).
| Type of Arrangement and Non-arrangement Transactions | FY 2015 | FY 2023 |
|---|---|---|
| Collaborative Arrangement | $57.20M | |
| Development & Commercialization Agreement | — | |
| Royalties (Non-Us) | $7.00K | |
| Total | $57.21M |
Theravance Biopharma brought in $57.21M from its two revenue lines in fiscal 2023, the year ended December 31, 2023. Collaborative Arrangement was the largest at $57.20M (100.0%), ahead of Royalties (Non-Us) at $7.00K (0.0%).
Theravance Biopharma (TBPH) reports its revenue by product and service, by geography and by type of arrangement and non-arrangement transactions. In fiscal 2025, Collaboration Agreement was its largest product and service line, bringing in $74.96M (69.8% of the total), followed by Milestone at $25.00M (23.3%).
Collaboration Agreement was Theravance Biopharma's largest product and service line in fiscal 2025, bringing in $74.96M, or 69.8% of the $107.46M total across its three product and service lines.
United States was Theravance Biopharma's largest region in fiscal 2025, bringing in $74.96M, or 69.8% of the $107.46M total across its two regions.
Collaborative Arrangement was Theravance Biopharma's largest revenue line in fiscal 2023, bringing in $57.20M, or 100.0% of the $57.21M total across its two revenue lines.
Every figure comes from Theravance Biopharma's annual financial filings, as reported. Each line keeps the name Theravance Biopharma gives it, and years follow its fiscal calendar.
Theravance Biopharma's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.